文献速递介入腹部CTDSA

可降解淀粉微球经动脉化疗栓塞(DSM-TACE)作为索拉非尼停药或不适合索拉非尼的肝细胞癌患者的二线治疗

TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib.
PubMed 文献 · Eur Radiol · 2018-08-31

该前瞻性研究纳入40例不适合或停用索拉非尼的中期或局部晚期肝细胞癌(BCLC B或C期)患者,行经动脉化疗栓塞联合可降解淀粉微球(DSM-TACE)治疗。作者认为DSM-TACE作为二线治疗安全有效。

要点

  • 1年总疾病控制率为52.5%,中位无进展生存期6.4个月,中位总生存期11.3个月。
  • DSM可暂时闭塞较小动脉血管,减少细胞抑制剂立即洗脱,提高整体疗效并降低全身毒性及栓塞后综合征风险。

核心结论

  • DSM-TACE作为停用或不适合索拉非尼的HCC患者的二线治疗安全有效。

研究设计与样本

  • 前瞻性研究,连续纳入40例BCLC B或C期、停用或不适合索拉非尼的中期或局部晚期HCC患者(31例男性,年龄70.6±13.6岁),经叶段入路行DSM-TACE治疗,采用多排CT基于mRECIST标准评估肿瘤反应。

诊断标准与关键数值

  • 肿瘤反应采用多排CT基于mRECIST标准评估;1年总疾病控制率为52.5%,中位无进展生存期6.4个月,中位总生存期11.3个月。

临床应用与阅片要点

  • 作者认为DSM-TACE可作为停用或不适合索拉非尼的HCC患者的二线治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To date, there is no approved second-line treatment for patients dismissing sorafenib or ineligible for this treatment, so it would be useful to find an effective alternative treatment option. The aim of our study was to evaluate safety, feasibility and effectiveness of transarterial chemoembolisation with degradable starch microspheres (DSM-TACE) in the treatment of patients with advanced hepatocellular carcinoma (HCC) dismissing or ineligible for multikinase-inhibitor chemotherapy administration (sorafenib) due to unbearable side effects or clinical contraindications.

METHODS: Forty consecutive BCLC stage B or C patients (31 male; age, 70.6 ± 13.6 years), with intermediate or locally advanced HCC dismissing or ineligible for sorafenib administration, who underwent DSM-TACE treatment cycle via lobar approach were prospectively enrolled. Tumour response was evaluated on multidetector computed tomography based on mRECIST criteria. Primary endpoints were safety, tolerance and overall disease control (ODC); secondary endpoints were progression-free survival (PFS) and overall survival (OS).

RESULTS: Technical success was achieved in all patients. No intra/peri-procedural death/major complications occurred. No signs of liver failure or systemic toxicity were detected. At 1-year follow-up, ODC of 52.5% was registered. PFS was 6.4 months with a median OS of 11.3 months.

CONCLUSIONS: DSM-TACE is safe and effective as a second-line treatment in HCC patients dismissing or ineligible for sorafenib.

KEY POINTS: • DSM-TACE is safe and effective as second-line treatment in HCC patients dismissing or ineligible for sorafenib • DSM-TACE allows the temporary occlusion of the smaller arterial vessels, improving overall therapeutic effectiveness by reducing the immediate wash-out of the cytostatic agent • DSM-TACE also decreases the risk of systemic toxicity and post-embolic syndrome.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Iezzi R, Pompili M, Rinninella E, et al. TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib. Eur Radiol. 2018. PMID: 30171360. doi:10.1007/s00330-018-5692-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。